Determination of Epidermal Growth Factor Receptor (EGFR), KRAS and BRAF Mutation in Non Small Cell Lung Cancers Using Biofilm Chip Based Microarray Technology

Abstract

Background: In this study, it vi cell lung carcinoma. Methods: 96 lung resection materials; it was examined for the presence of TNM (The TNM Staging System is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M)) stage, smoking, age, sex, tumor differentiation and EGFR, KRAS and BRAF mutations. Results: Of the 96 patients included in the study, 58 were adenocarcinomas, 30 were squamous cell carcinomas (SCC), and 8 were large cell neuroendocrine carcinomas (LCNEC). While EGFR mutation was detected in 14 (24.1%) of the adenocarcinoma patients, KRAS mutation was detected in 12 (20.6%) patients. BRAF mutation was observed in 1 patient with adenocarcinoma (1.7%). KRAS mutation was observed in only 1 of the SCCs (3.3%). KRAS mutation was observed in 1 of the LCNECs (12.5%). EGFR mutation in adenocarcinoma cases was found to be significantly associated with female gender and nonsmoking status. There was no correlation between EGFR mutation and age, stage, tumor size, lymph node metastasis, distant metastasis and differentiation grade. No correlation was found between KRAS mutation and other factors. The BRAF mutation could not be assessed for association because the number of cases monitored was low. The microarray method we used in our study provided the scanning of the cases in terms of 50 different mutations commonly identified for the EGFR gene, single chip 24 different mutations for KRAS and BRAF gene in a total of 96 cases with NSCLC (Non Squamous Cell Lung Cancer) in three different subtypes at the same time and in a short time. We think our study will be useful in the development of treatment protocols and patient selection.